First Results From a Randomized Phase 2 Study of Cabazitaxel vs an Androgen Receptor-Targeted Agent in Patients With Poor-Prognosis Castration-Resistant Prostate Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [1] First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).
    van der Zande, Kim
    van der Noort, Vincent
    Busard, Milou
    Hamberg, Paul
    Ras-van Spijk, Suzan
    De Feijter, Jeantine
    Dezentje, Vincent O.
    Tascilar, Metin
    Houtsma, Danny
    Beeker, Aart
    van den Berg, H. Pieter
    ten Oever, Diederik
    Oving, Irma M.
    Zwart, Wilbert
    Bergman, Andre M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Final results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC)
    van der Zande, K.
    van der Noort, V.
    Busard, M.
    Hamberg, P.
    Ras-van Spijk, S.
    de Feijter, J.
    Dezentje, V.
    Tascilar, M.
    Houtsma, D.
    Beeker, A.
    van den Berg, P.
    ten Oever, D.
    Oving, I. M.
    Zwart, W.
    Bergman, A. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S985 - S985
  • [3] Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents
    Angelergues, Antoine
    Efstathiou, Eleni
    Gyftaki, Revekka
    Wysocki, Piotr Jan
    Lainez, Nuria
    Gonzalez, Iria
    Castellano, Daniel E.
    Ozguroglu, Mustafa
    Garcia Carbonero, Iciar
    Flechon, Aude
    Borrega, Pablo
    Guillot, Aline
    Campos Balea, Begona
    Le Moulec, Sylvestre
    Esteban, Emilio
    Munarriz, Javier
    Rubio, Gustavo
    Birtle, Alison J.
    Delanoy, Nicolas
    Bellmunt, Joaquim
    Oudard, Stephane
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E777 - E784
  • [4] Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
    Matsubara, Nobuaki
    Yamada, Yoko
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    Yano, Akihiro
    Kawakami, Satoru
    Otsuka, Masafumi
    Fukasawa, Satoshi
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E1073 - E1080
  • [5] Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer
    Saad, F.
    Chi, K. N.
    Shore, N.
    Graff, J. N.
    Posadas, E. M.
    Freeman, S.
    Tryon, J.
    Trudel, G. C.
    de Jong, J.
    Meltzer, J.
    Zhao, X.
    Tran, N.
    Rezazadeh, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 292 - 292
  • [6] A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC)
    Chi, K. N.
    Taavitsainen, S.
    Iqbal, N.
    Ferrario, C.
    Ong, M.
    Wadhwa, D.
    Hotte, S. J.
    Lo, G.
    Tran, B.
    Azad, A.
    Wood, L.
    Gingerich, J. R.
    North, S.
    Pezaro, C. V.
    Ruether, D.
    Sridhar, S. S.
    Annala, M.
    Bacon, J.
    Wyatt, A. W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy
    Ingrosso, G.
    Detti, B.
    Fodor, A.
    Caini, S.
    Borghesi, S.
    Triggiani, L.
    Trippa, F.
    Russo, D.
    Bruni, A.
    Francolini, G.
    Lancia, A.
    Marinelli, L.
    Di Muzio, N.
    Livi, L.
    Magrini, S. M.
    Maranzano, E.
    Musio, D.
    Aristei, C.
    Valeriani, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (08): : 1577 - 1584
  • [8] Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: A retrospective multicenter study
    Iwamura, Hiromichi
    Hatakeyama, Shingo
    Narita, Shintaro
    Arai, Yoichi
    Habuchi, Tomonori
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (01) : 125 - 127
  • [9] Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy
    G. Ingrosso
    B. Detti
    A. Fodor
    S. Caini
    S. Borghesi
    L. Triggiani
    F. Trippa
    D. Russo
    A. Bruni
    G. Francolini
    A. Lancia
    L. Marinelli
    N. Di Muzio
    L. Livi
    S. M. Magrini
    E. Maranzano
    D. Musio
    C. Aristei
    M. Valeriani
    Clinical and Translational Oncology, 2021, 23 : 1577 - 1584
  • [10] Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Saad, Fred
    Chi, Kim N.
    Shore, Neal D.
    Graff, Julie Nicole
    Posadas, Edwin M.
    Espina, Byron M.
    Zhu, Eugene
    Hazra, Anasuya
    Bradic, Branislav
    Cheng, Shinta
    Hayreh, Vinny
    Rezazadeh, Arash
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345